CureFSGS
Financiado
Decode and Cure primary Focal Segmental Glomerulosclerosis
Kidney diseases are a worldwide rising major health problem associated with an excess risk for cardiovascular disease and reduced life expectancy. While general risk factors for kidney diseases such as diabetes and hypertension ar...
Kidney diseases are a worldwide rising major health problem associated with an excess risk for cardiovascular disease and reduced life expectancy. While general risk factors for kidney diseases such as diabetes and hypertension are being addressed through numerous research efforts, causes of specific glomerular kidney diseases, especially Focal Segmental Glomerulosclerosis (FSGS), remain poorly understood. FSGS is the most common glomerular cause of end stage renal disease characterized by scaring of the glomerular kidney filters and podocytes loss. Until now, the development of specific therapies has been hindered by the poor stratification of FSGS entities and the lack of understanding of immune mediated forms of FSGS. CureFSGS will establish a new strategy to identify key factors in FSGS: First, CureFSGS will develop a molecular classification of FSGS entities by utilizing a worldwide unique kidney sample repository/ registry combined with a novel analysis pipeline of single cell analytics, multiplex imaging and machine learning-aided image analysis to guide clinical decision making and to provide novel molecular insights. Second, CureFSGS will precisely decode immune mediators of FSGS and systematically map the podocyte response towards immune actions by devising a novel complementary platform of immune cell analytics and podocyte in vitro, ex vivo perfused kidney, in vivo as well as human organoid systems. Third, CureFSGS will ultimately precision target the identified immune cells, soluble immune factors or podocyte injury pathways by newly developed cell-specific AAV- and nanobody strategies. Together, CureFSGS will set the stage to finally understand and treat FSGS effectively.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2025-01-01
Fecha Fin: 2029-12-31
Fecha Fin: 2029-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5